History & Mission Statement


Oligomerix was founded in 2006 and has focused its research efforts on the role of tau protein, specifically tau oligomers as a key mechanism in disease progression in various tauopathies including Alzheimer’s, frontotemporal dementia, PSP, Parkinson’s and early-onset dementia.

Oligomerix’s Mission

To discover and develop novel small molecule DMTs and biomarkers for AD/RD by targeting tau self-association into oligomers. The Company intends to be a leader in the tau-targeting field.